Essential Thrombocythemia Clinical Trials

104 clinical trials for Essential Thrombocythemia across international registries, including 25 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) — RECRUITING · PHASE2
• Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes — RECRUITING · NA
• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — RECRUITING · PHASE3
• Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis — RECRUITING · PHASE1
• Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm — RECRUITING
• Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms — RECRUITING · PHASE2
• AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms — RECRUITING · PHASE3
• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms — RECRUITING · PHASE2
• An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms — RECRUITING · PHASE1
• Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) — RECRUITING · NA
• MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) — RECRUITING
• Ruxolitinib in Thrombocythemia and Polycythemia Vera — RECRUITING · PHASE2
• MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial — RECRUITING · PHASE2
• Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET — RECRUITING · PHASE2
• Two Step Haplo With Radiation Conditioning — RECRUITING · PHASE2
• A Study of GLB-001 in Patients With Myeloid Malignancies — RECRUITING · PHASE1
• Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm — RECRUITING · PHASE1
• Efficacy and Safety of Peginterferon in ET and PV. — RECRUITING · NA
• Myeloproliferative Neoplasms (MPNs) Patient Registry — RECRUITING
• Myeloproliferative Neoplastic Diseases Observatory From Brest — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-COMPARATOR-CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BOMEDEMSTAT (MK-3543) VERSUS HYDROXYUREA IN CYTOREDUCTIVE THERAPY NAÏVE ESSENTIAL THROMBOCYTHEMIA PARTICIPANTS — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-COMPARATOR-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BOMEDEMSTAT (MK-3543/IMG-7289) VERSUS BEST AVAILABLE THERAPY (BAT) IN PARTICIPANTS WITH ESSENTIAL THROMBOCYTHEMIA WHO HAVE AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA — RECRUITING · PHASE3
• Asian Myeloproliferative Neoplasm (MPN) Registry — RECRUITING
• A SINGLE-ARM, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF ROPEGINTERFERON ALFA-2B-AJFT (P1101) IN ADULT PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA — RECRUITING
• A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED STUDY TO ASSESS PHARMACOKINETICS AND COMPARE THE EFFICACY, SAFETY, AND TOLERABILITY OF P1101 VS ANAGRELIDE AS SECOND LINE THERAPY FOR ESSENTIAL THROMBOCYTHEMIA (SURPASS ET): THE CORE STUDY AND ITS EXTENSION STUDY — RECRUITING · PHASE3
• The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) — ACTIVE_NOT_RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF INCA033989 VERSUS BEST AVAILABLE THERAPY IN PARTICIPANTS WITH ESSENTIAL THROMBOCYTHEMIA AND A CALR MUTATION PREVIOUSLY TREATED WITH CYTOREDUCTIVE THERAPY (EXCALIBUR-ET2) — NOT_YET_RECRUITING · PHASE3
• Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance — ACTIVE_NOT_RECRUITING · PHASE3
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) — ACTIVE_NOT_RECRUITING · PHASE3
• Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA) — NOT_YET_RECRUITING
• A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants — TERMINATED · PHASE3
• Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) — COMPLETED · PHASE2
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms — TERMINATED · PHASE1
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies — COMPLETED · PHASE2
• Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea — TERMINATED · PHASE2
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING
• IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) — ACTIVE_NOT_RECRUITING · PHASE2
• A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET — ACTIVE_NOT_RECRUITING · PHASE2
• Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders — COMPLETED · PHASE1
• Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms — ACTIVE_NOT_RECRUITING
• Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. — COMPLETED · NA
• Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients — COMPLETED · PHASE2
• Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms — COMPLETED
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant — COMPLETED · PHASE1
• Myeloproliferative Neoplasms: an In-depth Case-control Study — COMPLETED
• CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia — TERMINATED · PHASE1
• Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms — COMPLETED · NA

Refine this search